Today: Today, Ligand Pharmaceuticals Inc. (LGND) Director Jason Aryeh Sold 18,479 Shares

Today, Ligand Pharmaceuticals Inc. (LGND) Director Jason Aryeh Sold 18,479 Shares

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh sold 18,479 shares of the company’s stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $107.31, for a total transaction of $1,982,981.49. Following the transaction, the director now owns 58,959 shares in the company, valued at approximately $6,326,890.29. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Jason Aryeh also recently made the following trade(s): On Friday, November 18th, Jason Aryeh sold 6,330 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $105.28, for a total transaction of $666,422.40.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) traded down 0.06% during midday trading on Friday, reaching $106.77. 144,372 shares of the company traded hands. Ligand Pharmaceuticals Inc. has a 1-year low of $82.06 and a 1-year high of $139.79. The stock has a market capitalization of $2.23 billion, a P/E ratio of 305.93 and a beta of 1.43. The firm has a 50-day moving average of $98.66 and a 200-day moving average of $112.47.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its earnings results on Thursday, November 3rd. The biotechnology company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.03. Ligand Pharmaceuticals had a return on equity of 9.98% and a net margin of 8.51%. The company had revenue of $21.62 million for the quarter, compared to analyst estimates of $23.64 million. During the same quarter in the previous year, the firm earned $0.57 earnings per share. The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. On average, analysts predict that Ligand Pharmaceuticals Inc. will post $3.40 earnings per share for the current year.

Several large investors have recently modified their holdings of LGND. Victory Capital Management Inc. raised its stake in shares of Ligand Pharmaceuticals by 168,987.6% in the third quarter. Victory Capital Management Inc. now owns 940,127 shares of the biotechnology company’s stock worth $95,949,000 after buying an additional 939,571 shares during the last quarter. Emerald Acquisition Ltd. acquired a new stake in shares of Ligand Pharmaceuticals during the second quarter worth $44,004,000. Mesirow Financial Investment Management Equity Management acquired a new stake in shares of Ligand Pharmaceuticals during the second quarter worth $20,912,000. Atlantic Trust Group LLC acquired a new stake in shares of Ligand Pharmaceuticals during the second quarter worth $20,024,000. Finally, State of New Jersey Common Pension Fund D acquired a new stake in shares of Ligand Pharmaceuticals during the second quarter worth $17,891,000.

Several equities analysts have issued reports on LGND shares. Deutsche Bank AG cut shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating and upped their target price for the company from $104.00 to $110.00 in a research note on Friday, August 5th. They noted that the move was a valuation call. Roth Capital restated a “buy” rating and set a $149.00 target price (up previously from $147.00) on shares of Ligand Pharmaceuticals in a research note on Friday, August 5th. Vetr upgraded shares of Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $128.29 target price on the stock in a research note on Wednesday, August 10th. Zacks Investment Research cut shares of Ligand Pharmaceuticals from a “strong-buy” rating to a “sell” rating in a research note on Tuesday, October 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $160.00 price objective (up previously from $146.00) on shares of Ligand Pharmaceuticals in a research note on Wednesday, October 5th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $139.70.

About Ligand Pharmaceuticals

Related posts

Leave a Comment